NCT06734871招募中1 期
A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1190B CAR-T Cell Therapy, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Aibin Liang，MD，Ph.D.1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2024年12月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Adverse Events (AE) after CT1190B infusion
研究概览
简要总结
A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1190B CAR-T Cell therapy, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
详细描述
This is a single-arm, open-label, dose exploratory clinical study to evaluate the safety, efficacy, cellular pharmacokinetics, and pharmacodynamics of CT1190B cells in patients with B-NHL. It is planned to enroll 6-24 participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must voluntarily sign the informed consent form (ICF) and must be willing and be able to adhere to the study visit schedule and other protocol requirements and agree to be in long term follow-up (LTFU) for up to 15 years as mandated by the regulatory guidelines.
- •18-75 years old;
- •Histologically or cytologically confirmed B-NHL;
- •Previously received at least 2 lines of systemic therapy;
- •Intolerance to last treatment, or have progressed on or after the last treatment and currently require therapy;
- •There are measurable target lesions;
- •Expected survival > 12 weeks;
- •Eastern Cooperative Oncology Group (ECOG) score 0-1;
- •Female participants of childbearing potential must have a negative pregnancy test at screening and prior to receiving preconditioning therapy and are willing to use a highly effective and reliable method of contraception for 1 year after receiving study treatment and are absolutely prohibited from donating eggs for 1 year after receiving study treatment infusion during the study; male participants are willing to use a highly effective and reliable method of contraception for 1 year after receiving study treatment if they are sexually active with a female of childbearing potential. Sperm donation is absolutely prohibited for 1 year after receiving study treatment infusions during the study for all male participants.
排除标准
- •Pregnant or lactating women;
- •Has HIV, syphilis infection, active hepatitis B virus infection (HBsAg positive and HBV-DNA above the detection limit), or active hepatitis C virus infection (HCV antibody and HCV-DNA positive);
- •Has any current uncontrolled active infection, including but not limited to participants with active tuberculosis (investigator 's judgment);
- •Participants' toxicities caused by previous treatment did not recover to Common Terminology Criteria for Adverse Events (CTCAE) ≤ Grade 1, except alopecia and other events that are judged tolerable by the investigator;
- •Has received treatment for the disease within 14 days before informed consent, including but not limited to cytotoxic therapy, monoclonal antibodies or ADCs, targeted therapy, radiotherapy, epigenetic therapy, or investigational agents, or invasive investigational medical devices within 14 days before informed consent. If the radiation field covers ≤ 5% of the bone marrow reserve, the participant is eligible regardless of the end date of radiotherapy;
- •Systemic glucocorticoids equivalent to > 15 mg/day prednisone within 7 days prior to informed consent, with the exception of topical glucocorticoids;
- •Vaccination with live attenuated vaccines, inactivate vaccines or RNA vaccines within 4 weeks prior to informed consent;
- •Participants who are allergic or intolerant to preconditioning drugs, tocilizumab, or have other previous history of severe allergy such as anaphylactic shock;
- •Patients with any heart disease in the 6 months prior to screening;
- •Oxygen saturation < 92%,;
- •Presence of a second primary malignancy requiring treatment or not in complete remission within the past 2 years;
- •Major surgery within 2 weeks before informed consent or planned during the study period or within 4 weeks after giving study treatment (excluding local anesthesia such as cataract);
- •Participants are unable or unwilling to comply with the requirements of the study protocol or are otherwise unsuitable for participating in this clinical study in the investigator 's assessment;
研究组 & 干预措施
CAR-T cells（ chimeric antigen receptor T cells）
Experimental
CT1190B cells infusion
干预措施: CAR T cells (Drug)
结局指标
主要结局
Adverse Events (AE) after CT1190B infusion
时间窗: 12 months after CT1190B infusion
An assessment of severity grade will be made according to the National Cancer Institute Common Terminology Criteria
MTD and/or dose range
时间窗: Up to 28 days after CAR-T cells infusion
Evaluate Dose limited toxicity and recommended dosage range after CT0991 infusion
次要结局
- Overall response rate（ORR）(Evaluate at 4, 8, 12 weeks and 6,9,12month after CAR-T infusion)
- Complete response rate (CRR)(12 months after CT1190B infusion)
- Duration of remission(DOR)(12 months after CT1190B infusion)
- Time to response (TTR)(12 months after CT1190B infusion)
- Time to complete response (TTCR)(12 months after CT1190B infusion)
- Progression-free survival (PFS)(12 months after CT1190B infusion)
- Overall survival (OS)(12 months after CT1190B infusion)
研究者
Aibin Liang，MD，Ph.D.
Principal Investigator
Shanghai Tongji Hospital, Tongji University School of Medicine
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell LeukemiaRelapsed/Refractory Plasma Cell LeukemiaRelapsed/Refractory Multiple MyelomaNCT06730256The First Affiliated Hospital of Soochow University24
尚未招募
1 期
A Study of CAR-T Cells in Subjects with Autoimmune DiseasesAutoimmune DiseasesNCT06762119Zhejiang University6
暂停
1 期
Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell MalignanciesPeripheral T Cell LymphomaAngioimmunoblastic T-cell LymphomaAnaplastic LymphomaAcute T Cell LeukemiaT-lymphoblastic LymphomaNCT04828174Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine9
招募中
1 期
Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBLT Cell Lymphoblastic LymphomaNCT05554575Bioceltech Therapeutics, Ltd.15
Unknown
早期 1 期
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT04626752Hebei Senlang Biotechnology Inc., Ltd.50